



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

3 December 2012

CHANGE IN BOARD COMPOSITION

Bioxyne Limited (ASX: BXN or the Company) announces the following changes in board composition pursuant to the results of its Annual General Meeting held in Sydney on 29th November 2012.

Dr William Harrison has relinquished his role as a director of the Company as the votes for his re-election was less than the required 50.1% of proxies voted by shareholders. On behalf of the Company I thank him for his significant contributions during his tenure as a Director. The board and the Company wish him well with his future endeavours.

Mr Ian Mutton, also announced his retirement as Chairman of the Board prior to the commencement of the AGM. Mr Mutton has chaired the Company since 2008 when he joined the Hunter Immunology Limited Board. During his tenure, Mr Mutton led the Company to its current listing on the ASX. On behalf of the board and long term shareholders of the Company I thank Mr Mutton for his contributions and wish him well for the future.

Mr Anthony Ho was appointed Chairman of Bioxyne. Mr Ho brings extensive experience as a Director, and is chairman and non executive director of four other listed companies. The current Board of Directors comprises Mr Ho, Mr Patrick Ford and Mr David Radford.

In consultation with major stakeholders, the board will seek additional directors to augment its skills that are relevant with its life science based technology business.

**Anthony P. Ho
Chairman**



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



For Further information please contact:

David Radford
Chief Executive Officer
Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com

COPD

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. More than 15 per cent of new patients have never smoked and industrial pollution is viewed as a major risk factor in the onset of COPD. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer.